Garry Neil

2021

In 2021, Garry Neil earned a total compensation of $1.2M as Chief Executive Officer, President, Chairman of the Board and principal executive officer at Avalo Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$239,587
Option Awards$571,484
Salary$423,000
Total$1,234,071

Neil received $571.5K in option awards, accounting for 46% of the total pay in 2021.

Neil also received $239.6K in non-equity incentive plan and $423K in salary.

Rankings

In 2021, Garry Neil's compensation ranked 8,017th out of 12,412 executives tracked by ExecPay. In other words, Neil earned more than 35.4% of executives.

ClassificationRankingPercentile
All
8,017
out of 12,412
35th
Division
Manufacturing
3,546
out of 5,498
36th
Major group
Chemicals And Allied Products
1,577
out of 2,374
34th
Industry group
Drugs
1,402
out of 2,095
33rd
Industry
Pharmaceutical Preparations
1,039
out of 1,542
33rd
Source: SEC filing on October 19, 2023.

Neil's colleagues

We found four more compensation records of executives who worked with Garry Neil at Avalo Therapeutics in 2021.

2021

Michael Cola

Avalo Therapeutics

Chief Executive Officer

2021

Schond Greenway

Avalo Therapeutics

Chief Financial Officer

2021

H Wilkins

Avalo Therapeutics

Chief Medical Officer

2021

Christopher Sullivan

Avalo Therapeutics

Chief Financial Officer

News

You may also like